Previous studies have shown that overexpression of human
apolipoprotein C-I (
apoC-I) results in moderate
hypercholesterolemia and severe
hypertriglyceridemia in mice in the presence and absence of
apoE. We assessed whether physiological endogenous
apoC-I levels are sufficient to modulate plasma
lipid levels independently of effects of
apoE on lipid metabolism by comparing
apolipoprotein E gene-deficient/
apolipoprotein C-I gene-deficient (
apoe-/-apoc1-/-),
apoe-/-apoc1+/-, and
apoe-/-apoc1+/+ mice. The presence of the
apoC-I gene-dose-dependently increased plasma
cholesterol (+45%; P < 0.001) and
triglycerides (TGs) (+137%; P < 0.001), both specific for VLDL. Whereas
apoC-I did not affect intestinal [3H]TG absorption, it increased the production rate of hepatic VLDL-TG (+35%; P < 0.05) and VLDL-[35S]
apoB (+39%; P < 0.01). In addition,
apoC-I increased the postprandial TG response to an intragastric
olive oil load (+120%; P < 0.05) and decreased the uptake of [3H]TG-derived FFAs from intravenously administered VLDL-like
emulsion particles by gonadal and perirenal white adipose tissue (WAT) (-34% and -25%, respectively; P < 0.05). As LPL is the main
enzyme involved in the clearance of TG-derived FFAs by WAT, and total postheparin plasma LPL levels were unaffected, these data demonstrate that endogenous
apoC-I suffices to attenuate the lipolytic activity of LPL. Thus, we conclude that endogenous plasma
apoC-I increases VLDL-total
cholesterol and VLDL-TG dose-dependently in
apoe-/- mice, resulting from increased VLDL particle production and LPL inhibition.